Clinical Study

Nrg-Gi004- Colorectal Cancer Metastatic Dmmr Immuno-Therapy (Commit) Study: A Randomized Phase III Study Of Mfolfox6/Bevacizumab Combination Chemotherapy With Or Without Atezolizumab Or Atexolizumab Monotherapy In The First-Line Treatment Of Patients With

Posted Date: May 15, 2019

  • Investigator: Jordan Kharofa
  • Specialties: Cancer, Colorectal Cancer, Oncology
  • Type of Study: Drug

The goal of this study is to determine the efficacy, based on progression free survival, of mFOLFOX6/bevacizumab plus atezolizumab and atezolizumab as compared to mFOLFOX6/bevacizumab

Criteria:

To Be Eligible To Participate In This Study, Patients Must Have Colorectal Cancer, Age 18 Or Older, Nonpregnant, No Uncontrolled High Bp, No Other Malignancies Or Active Infections.

Keywords:

Colorectal Cancer, Gastrointestinal, Phase Iii, S1610

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.